BERGENBIO ANNOUNCES CHANGES TO SENIOR MANAGEMENT
Bergen, Norway, 6 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces changes to its clinical development team structure in preparation for late-stage clinical trials of lead candidate bemcentinib and increased activity in medical and scientific regulatory affairs. Prof. Hani Gabra has transitioned from Chief Medical Officer to a part-time position as Director of Clinical Development, to focus on the scientific elements of clinical trial design and the